Eli Lilly and Company (LLY)vsZevra Therapeutics Inc. (ZVRA)
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
ZVRA
Zevra Therapeutics Inc.
$10.17
+5.17%
HEALTHCARE · Cap: $585.24M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 61118% more annual revenue ($65.18B vs $106.47M). ZVRA leads profitability with a 78.2% profit margin vs 31.7%. LLY appears more attractively valued with a PEG of 1.29. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
ZVRA
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+62.7%
Fair Value
$22.71
Current Price
$10.17
$12.54 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Attractively priced relative to earnings
Every $100 of equity generates 86 in profit
Keeps 78 of every $100 in revenue as profit
Revenue surging 183.4% year-over-year
Strong operational efficiency at 27.3%
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
0.0% earnings growth
Smaller company, higher risk/reward
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : ZVRA
The strongest argument for ZVRA centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 78.2% and operating margin at 27.3%. Revenue growth of 183.4% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : ZVRA
The primary concerns for ZVRA are EPS Growth, Market Cap, PEG Ratio.
Key Dynamics to Monitor
ZVRA carries more volatility with a beta of 0.89 — expect wider price swings.
ZVRA is growing revenue faster at 183.4% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 62/100), backed by strong 31.7% margins and 42.6% revenue growth. ZVRA offers better value entry with a 62.7% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Zevra Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company is headquartered in Celebration, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?